-
May 15, 2013
Generic forms of Pfizer’s once blockbuster comes with a price tag 85% lower than its patented equivalent, helping make significant savings for the NHS
Full story
-
March 19, 2013
Healthcare think-tank demands greater generic price cuts and an independent board to manage the growing medicines bill
Full story
-
February 25, 2013
Ranbaxy Laboratories has resumed manufacturing in the USA of its generic version of Lipitor after solving contamination problems
Full story
-
December 03, 2012
A few weeks after it recalled certain contaminated lots in the USA of generic atorvastatin, Ranbaxy has now stopped manufacturing its copy of Pfizer's blockbuster Lipitor as it gets to the bottom of the problem
Full story
-
November 23, 2012
Shares in Ranbaxy Laboratories have slipped after the Indian drugmaker recalled certain lots in the USA of atorvastatin, its generic version of Pfizer's cholesterol-lowerer blockbuster Lipitor
Full story
-
November 14, 2012
US drug giant Merck & Co has pulled the plug on an experimental combination of its diabetes drug Januvia and the cholesterol buster atorvastatin.
Full story
-
May 10, 2012
The entry of generic forms of Pfizer's blockbuster Lipitor (atorvastatin) onto the UK market could eventually save the National Health Service a whopping £350 million a year.
Full story
-
February 23, 2012
If Australia had paid English prices for generic simvastatin during May 2010-October 2011, its PBS spending could have been reduced from $150 million to just A$20 million, says a leading health economist.
Full story
-
December 02, 2011
Generics giant Teva Pharmaceutical Industries is all set to enter the lucrative market created in the USA by the patent expiry on Pfizer's Lipitor but not until Ranbaxy's 180-day exclusivity period runs out
Full story